Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting
up to 10 million people worldwide. PD has no cure yet, and patients rely only on …

Parkinson's disease (PD) is the second most common neurodegenerative disorder among
elderly population, characterized by the progressive degeneration of dopaminergic neurons …

In recent years, the contraposition between inflammatory and neurodegenerative processes
has been increasingly challenged. Inflammation has been emphasized as a key player in …

Parkinson's disease (PD) is characterised neuropathologically by the degeneration of
dopaminergic neurons in the ventral midbrain, the accumulation of α-synuclein (α-syn) …

Genetic studies on PARK genes have identified dysfunction in proteasomal, lysosomal, and
mitochondrial enzymes as pathogenic for Parkinson's disease (PD). We review the role of …

During Parkinson's disease (PD), both the central nervous system (CNS) and peripheral
nervous system (PNS) are affected. In parallel, innate immune cells respond early to …

Parkinson's disease (PD) is a neurodegenerative disorder where alpha-synuclein plays a
central role in the death and dysfunction of neurons, both, in central, as well as in the …

Current treatment options for Parkinson's disease (PD) typically aim to replace dopamine,
and hence only provide symptomatic relief. However, in the long run, this approach alone …

The brain is no longer considered an immune privileged organ and neuroinflammation has
long been associated with Parkinson's disease. Accumulating evidence demonstrates that …

Parkinson's disease (PD) is a common neurodegenerative disease characterized by loss of
dopaminergic neurons and intraneuronal accumulation of protein aggregates. The exact …